In Vancouver, Canada, on December 24, 2025, Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) announced its achievements over the year in developing innovative neuroplastogen-derived therapeutics. The company has been focusing on addressing prevalent health issues with limited treatment options. One of its key milestones includes the advancement of CMND-100, the leading candidate for treating Alcohol Use Disorder (AUD).